Table 1.
Antibacterial activity data for lipidated-vancomycin derivatives against vancomycin-sensitive and vancomycin-resistant bacteria.
| Compound |
S. aureus
(MSSA) ATCC 29213 |
S. aureus
(MRSA) ATCC 43300 |
E. .faecalis
(Van S) ATCC 29212 |
E. faecalis.
(Van B) ATCC 51299 |
E. faecalis
(Van A) MMX 486a |
|---|---|---|---|---|---|
| 9a | 0.25 | 0.25 | 0.5 | 1 | 16 |
| 9b | 0.12 | 0.12 | 0.25 | 0.25 | |
| 9c | 0.25 | 0.5 | 0.25 | 0.5 | 16 |
| 10 | 4 | 4 | 8 | 32 | >64 |
| 11 | 2 | 4 | 4 | 32 | >32 |
| 12 | 2 | 2 | 4 | 16 | >64 |
| 13 | 0.5 | 0.5 | 1 | 8 | >64 |
| 14 | 4 | 4 | 8 | 32 | >32 |
| 15 | 4 | 4 | 8 | 64 | >64 |
| Vancomycin | 1 | >64b | |||
| Teicoplanin | 1 | 0.5 | 0.25 | 0.25 | >64b |
| Linezolid | 4 | 4 | 2 | 2 | 2 |
a
MMX: Micromyx isolate number.
b
Vancomycin exhibits an MIC of 512 μg/mL and teicoplanin A2-2 exhibits an MIC of 128 μg/mL against Van A phenotype VRE strain, based on a literature report.37